Hengrui Medicine's application for the listing of CDK4/6 inhibitors has been accepted

分類：最新消息
作者：華訊知識產權
來源：
發布時間：2021-04-29 16:45
訪問量：

【概要描述】Hengrui Medicine's application for the listing of CDK4/6 inhibitors has been accepted On April 27, the Center for Drug Evaluation (CDE) announced that the new drug listing application submitted by Hengrui Medicine's Class 1 new drug CDK 4/6 (cyclin-dependent kinase 4 and 6)inhibitor SHR6390 tablets has been accepted, and the indication is: combined with Fulvestrant for hormone receptor (HR) positive and treatment of recurrent or metastatic breast cancer that is negative for human epidermal growth factor receptor 2 (HER2) after endocrine therapy. Breast cancer is the most common cancer among women worldwide. The most common subtype is the HR positive/HER2 negative subtype, which accounts for 70% of the total number of Breast cancer patients. Approximately 30% of patients diagnosed with HR-positive and HER2-negative early breast cancer are still at risk of cancer recurrence. At present, the combination therapy of CDK 4/6 inhibitors and endocrine drugs has become a new model for reversing the resistance of endocrine therapy, significantly improving the prognosis of patients with HR-positive advanced Breast cancer. CDK 4/6 is a key regulator that drives cell division. Studies have found that CDK 4/6 is overexpressed in many cancer cells, leading to uncontrolled cell division cycles and unlimited proliferation. Clinical studies have confirmed that more than half of breast cancer patients overexpress cyclin D (cyclin D), and most of them are HR-positive breast cancer patients. Because cyclin D directly acts on CDK 4/6, CDK 4/6 has become an important molecular target for patients with HR-positive metastatic breast cancer. SHR6390 is an oral, high-efficiency and selective small molecule CDK 4/6 inhibitor developed by Hengrui Medicine, which is a Class 1 new drug. It can selectively inhibit CDK 4/6 kinase activity, thereby blocking the CDK 4/6-retinoblastoma protein (Rb) signaling pathway, thereby inducing tumor cell G1 blockade, and selectively inhibiting the high expression of Rb Of tumor cells proliferate. Therefore, SHR6390 plays a decisive role in blocking the process of cells from G1 phase to S phase, thereby effectively inhibiting tumor cell proliferation, achieving the effect of anti-tumor and prolonging the survival of patients. Public information shows that SHR6390 has reached the pre-designated superiority standard in a multi-center, randomized, controlled, double-blind phase 3 clinical study named SHR6390-III-301. Compared with placebo and fulvestrant, it accepts SHR6390 combined with Fulvestrant can significantly prolong the progression-free survival of patients. The arrival of Hengrui Medicine SHR6390 is expected to bring new treatment options for breast cancer patients. ?

Hengrui Medicine's application for the listing of CDK4/6 inhibitors has been accepted

【概要描述】Hengrui Medicine's application for the listing of CDK4/6 inhibitors has been accepted

On April 27, the Center for Drug Evaluation (CDE) announced that the new drug listing application submitted by Hengrui Medicine's Class 1 new drug CDK 4/6 (cyclin-dependent kinase 4 and 6)inhibitor SHR6390 tablets has been accepted, and the indication is: combined with Fulvestrant for hormone receptor (HR) positive and treatment of recurrent or metastatic breast cancer that is negative for human epidermal growth factor receptor 2 (HER2) after endocrine therapy.

Breast cancer is the most common cancer among women worldwide. The most common subtype is the HR positive/HER2 negative subtype, which accounts for 70% of the total number of Breast cancer patients. Approximately 30% of patients diagnosed with HR-positive and HER2-negative early breast cancer are still at risk of cancer recurrence. At present, the combination therapy of CDK 4/6 inhibitors and endocrine drugs has become a new model for reversing the resistance of endocrine therapy, significantly improving the prognosis of patients with HR-positive advanced Breast cancer.

CDK 4/6 is a key regulator that drives cell division. Studies have found that CDK 4/6 is overexpressed in many cancer cells, leading to uncontrolled cell division cycles and unlimited proliferation. Clinical studies have confirmed that more than half of breast cancer patients overexpress cyclin D (cyclin D), and most of them are HR-positive breast cancer patients. Because cyclin D directly acts on CDK 4/6, CDK 4/6 has become an important molecular target for patients with HR-positive metastatic breast cancer.

SHR6390 is an oral, high-efficiency and selective small molecule CDK 4/6 inhibitor developed by Hengrui Medicine, which is a Class 1 new drug. It can selectively inhibit CDK 4/6 kinase activity, thereby blocking the CDK 4/6-retinoblastoma protein (Rb) signaling pathway, thereby inducing tumor cell G1 blockade, and selectively inhibiting the high expression of Rb Of tumor cells proliferate. Therefore, SHR6390 plays a decisive role in blocking the process of cells from G1 phase to S phase, thereby effectively inhibiting tumor cell proliferation, achieving the effect of anti-tumor and prolonging the survival of patients.

Public information shows that SHR6390 has reached the pre-designated superiority standard in a multi-center, randomized, controlled, double-blind phase 3 clinical study named SHR6390-III-301. Compared with placebo and fulvestrant, it accepts SHR6390 combined with Fulvestrant can significantly prolong the progression-free survival of patients.

The arrival of Hengrui Medicine SHR6390 is expected to bring new treatment options for breast cancer patients.

?

分類：最新消息
作者：華訊知識產權
來源：
發布時間：2021-04-29 16:45
訪問量：

詳情

Hengrui Medicine's application for the listing of CDK4/6 inhibitors has been accepted

On April 27, the Center for Drug Evaluation (CDE) announced that the new drug listing application submitted by Hengrui Medicine's Class 1 new drug CDK 4/6 (cyclin-dependent kinase 4 and 6)inhibitor SHR6390 tablets has been accepted, and the indication is: combined with Fulvestrant for hormone receptor (HR) positive and treatment of recurrent or metastatic breast cancer that is negative for human epidermal growth factor receptor 2 (HER2) after endocrine therapy.

Breast cancer is the most common cancer among women worldwide. The most common subtype is the HR positive/HER2 negative subtype, which accounts for 70% of the total number of Breast cancer patients. Approximately 30% of patients diagnosed with HR-positive and HER2-negative early breast cancer are still at risk of cancer recurrence. At present, the combination therapy of CDK 4/6 inhibitors and endocrine drugs has become a new model for reversing the resistance of endocrine therapy, significantly improving the prognosis of patients with HR-positive advanced Breast cancer.

CDK 4/6 is a key regulator that drives cell division. Studies have found that CDK 4/6 is overexpressed in many cancer cells, leading to uncontrolled cell division cycles and unlimited proliferation. Clinical studies have confirmed that more than half of breast cancer patients overexpress cyclin D (cyclin D), and most of them are HR-positive breast cancer patients. Because cyclin D directly acts on CDK 4/6, CDK 4/6 has become an important molecular target for patients with HR-positive metastatic breast cancer.

SHR6390 is an oral, high-efficiency and selective small molecule CDK 4/6 inhibitor developed by Hengrui Medicine, which is a Class 1 new drug. It can selectively inhibit CDK 4/6 kinase activity, thereby blocking the CDK 4/6-retinoblastoma protein (Rb) signaling pathway, thereby inducing tumor cell G1 blockade, and selectively inhibiting the high expression of Rb Of tumor cells proliferate. Therefore, SHR6390 plays a decisive role in blocking the process of cells from G1 phase to S phase, thereby effectively inhibiting tumor cell proliferation, achieving the effect of anti-tumor and prolonging the survival of patients.

Public information shows that SHR6390 has reached the pre-designated superiority standard in a multi-center, randomized, controlled, double-blind phase 3 clinical study named SHR6390-III-301. Compared with placebo and fulvestrant, it accepts SHR6390 combined with Fulvestrant can significantly prolong the progression-free survival of patients.

The arrival of Hengrui Medicine SHR6390 is expected to bring new treatment options for breast cancer patients.

關鍵詞：

上一個: 江北新區知識產權保護中心開展第129屆線上廣交會知識產權巡查工作

下一個: 先發表論文導致不言放棄的中科院走紅博士有了放棄

上一個: 江北新區知識產權保護中心開展第129屆線上廣交會知識產權巡查工作

下一個: 先發表論文導致不言放棄的中科院走紅博士有了放棄

2021年度專利復審無效十大案件

2021年度專利復審無效十大案件專利復審和無效審理是對專利權利的保護范圍大小甚至權利的有無進行再次認定的程序，決定著專利權的保護基礎，一直備受社會關注。4月26日，2021年度專利復審無效十大案件在國家知識產權局開放日活動中正式發布。案例1.“新穎的磺酰胺類化合物及其作為內皮素受體拮抗劑的應用”發明專利無效案（專利號：ZL01820481.3）案情簡介：專利權人：?？铺厝R茵藥品有限公司，無效宣告請求人：南京正大天睛制藥有限公司。本案涉及的藥品馬昔騰坦，是首個獲批用于治療肺動脈高壓的口服制劑。本案系仿制藥申請人在提交仿制藥申請后，針對原研藥發起的專利挑戰。案件審理過程中涉及化學醫藥領域的多個法律問題，包括權利要求中技術術語的理解、馬庫什權利要求的性質、馬庫什化合物和具體化合物優先權的認定、表格化合物充分公開的判斷、補充實驗數據以及化合物創造性的判斷等。審理結論：在修改的基礎上維持有效。典型意義：本案是藥物化合物審理的典型案例，對于優先權的認定、表格化合物充分公開的判斷以及化合物創造性的判斷具有示范作用。案例2.“被取代的多環性氨基甲?；拎ね苌锏那八帯卑l明專利無效案（專利號：ZL201180056716.8）案情簡介：專利權人：鹽野義制藥株式會社，無效宣告請求人：劉奕彤。本案涉及的瑪巴洛沙韋是目前獲批的首個、也是唯一一個單劑量口服抗流感藥物。案件審理過程中涉及馬庫什權利要求能否獲得說明書的支持，如何準確評價說明書對技術效果的公開以及結構類似的化合物的創造性判斷等法律問題。審理結論：維持有效典型意義：本案對于準確評價說明書描述的技術效果以及馬庫什權利要求能否得到說明書支持具有借鑒意義；還闡述了對于“結構類似但用途不同的化合物”，在創造性評判時應當對現有技術提供的機理研究成果進行全面考察，如果其與涉案專利的作用機制缺乏內在聯系，則不能從中獲得對化合物結構改進以實現不同用途的技術啟示。案例3.“通過圖像采集獲取網絡連接的數據傳輸方式及其系統”的發明專利無效案（專利號：ZL201010523284.4）案情簡介：專利權人為上?？贫冯娮涌萍加邢薰?，無效宣告請求人為掌閱科技股份有限公司。在本案的無效宣告程序中，雙方均提交了大量證據，案件復雜度高，口頭審理后，請求人提出了撤案聲明。本案審理的重點在于當請求人提出了撤案請求時，審理程序是否終止，即對專利法實施細則第七十二條第2款規定的理解和適用。審理結論：宣告無效典型意義：本案對于當事人撤回其請求但審理程序可以不終止的法律規定進行詮釋，合理平衡專利權人與社會公眾的利益。案例4.“左心耳封堵器”的發明專利無效案（專利號：ZL201310567987.0）案情簡介：專利權人：先健科技（深圳）有限公司，無效宣告請求人：蔡景莉。本案請求人對專利權人的多個專利權提起了無效宣告請求，本案是其中一件。本案審理中，請求人主張涉案專利缺乏新穎性和創造性，并提交相關現有技術證據。專利權人則主張請求人提出的主要證據屬于在申請日以前六個月內“他人未經申請人同意而泄露其內容的”情形，因而涉案專利應享有“新穎性寬限期”，請求人提交的證據不能破壞其新穎性和創造性。審理結論：宣告無效典型意義：本案對于“新穎性寬限期”的適用進行詮釋，充分論述了對“他人未經申請人同意而泄露其內容”能否享受現有技術豁免的認定思路，明確對于他人未經同意而泄露發明創造內容的情形，如果證據能夠表明專利權人在已經知曉情況后兩個月內仍未提出聲明和提交證明文件，則不能享有新穎性的寬限期。決定強調，專利權人在知曉他人未經同意而泄露技術內容時，應及時履行必要的聲明義務。案例5.“軸流風輪”的發明專利無效案（專利號：ZL200710026747.4）案情簡介：專利權人：廣東美的制冷設備有限公司，無效宣告請求人：珠海格力電器股份有限公司。美的、格力、奧克斯是國內空調行業的三大競爭巨頭，他們之間的專利紛爭不斷，本案為格力對美的提出的第二次無效宣告請求，案件所涉及的用于空調外機上的軸流風輪對空調效能具有重要影響，是三家企業專利大戰的關鍵專利之一。審理結論：宣告無效典型意義：本案涉及單方委托鑒定報告證據效力的認定，同時，對采用參數定義的產品權利要求與使用公開證據的技術比對提供了審理思路。 ? 案例6.“圖像傳感器CS3825C”的集成電路布圖設計專有權撤銷案（登記號：BS.175539928）案情簡介：專利權人：珠海市矽旺半導體有限公司，撤銷意見提出人：深圳市芯智銳光電科技有限公司。本案審理涉及多個撤銷條款，包括有關保護客體的條例第二條，有關獨創性的條例第四條，有關申請登記期限的條例第七條。審理結論：維持有效典型意義：本案詮釋了專有權保護對象、獨創性審理范圍以及申請登記期限的判斷規則，對布圖設計案件的審理具有借鑒意義。案例7.“儀表機殼”的外觀設計專利無效案（專利號：ZL201030122941.5）案情簡介：專利權人：福建順昌虹潤精密儀器有限公司，無效宣告請求人：廈門?？谱詣踊萍加邢薰?。本案審理過程中涉及多個爭議焦點，包括“中間產品”是否屬于外觀設計保護的客體、判斷主體的確定，以及外觀設計的對比判斷規則。審理結論：宣告無效典型意義：本案闡明了作為判斷主體的“一般消費者”應當具有的知識水平和認知能力，分析了各設計特征對于整體視覺效果的不同影響權重。案例8.“防爆裝置”的實用新型專利無效案（專利號：ZL201521112402.7）案情簡介：專利權人：寧德時代新能源科技股份有限公司，無效宣告請求人：江蘇塔菲爾新能源科技股份有限公司、東莞塔菲爾新能源科技有限公司。本案審理過程中主要爭議焦點在于兩個方面，一是對技術方案的理解，二是作為技術改進點的多個結構特征對創造性判斷的影響。審理結論：在修改的基礎上維持有效。典型意義：本案是新能源領域結構類產品創造性判斷的典型案例，決定強調，判斷是否存在技術啟示時，應對區別特征之間的關系予以關注，在準確認定涉案專利實際要解決的技術問題和能夠達到的技術效果的基礎上，客觀判斷現有技術是否給出了相應的技術啟示。案例9.“用于治療潛伏性結核的喹啉衍生物”?“取代的喹啉衍生物在治療耐藥性分枝桿菌性疾病中的用途”的發明專利無效案（專利號：ZL201210507318.X、ZL200580017016.2）案情簡介：專利權人：詹森藥業有限公司，無效宣告請求人：王立群。本系列案涉及兩項專利權，該兩項專利涉及全球45年來首個抗結核藥物“貝達喹啉”。本系列案審理過程中涉及多個爭議焦點，包括對權利要求特定技術術語的理解、如何考量說明書實驗數據，以及對醫藥用途發明改進動機與合理成功預期的判斷等。審理結論：在修改的基礎上維持有效。典型意義：本案明確了在醫藥用途發明的創造性判斷中，應當準確評價是否存在“合理的成功預期”。案例10.“一種用于給排水的活接接頭”的實用新型專利無效案（專利號：ZL201920390483.9）案情簡介：專利權人：浙江天雁控股有限公司，無效宣告請求人：孟祥麟。本案審理過程中涉及舉證責任、對電子證據真實性的確定、使用公開證據鏈的認定，以及實用性的判斷等諸多法律問題。審理結論：維持有效。典型意義：本案明晰了在核實證據優先權時，本國優先權文件的舉證責任分配和獲取途徑。同時，本案還詮釋了對實用性意義上“能夠產生積極效果”的理解，以及對微信聊天記錄、展會等不同類型證據真實性和證明力的認定規則。 ? ? ?

2022-05-13

The 2021 patent index targets current patent statistics and trends in Europe

The EPO acts as executive body for the European Patent Organization, an intergovernmental organization that was set up on 7 October 1977 on the basis of the?European Patent Convention, to “strengthen co-operation between the States of Europe in respect of the protection of inventions” and establish a single procedure for the grant of patents abiding by certain standard rules.

2022-04-22

Chile is the first country to pass neurorights law

On October 25th, 2021, the Senate of the Republic of Chile unanimously approved a bill to amend the constitution to protect brain rights or “neurorights”. Chile became the first nation to have a constitution in force that explicitly addresses the challenges of emerging neurotechnologies.?

2022-04-15